ANMerge: A Comprehensive and Accessible Alzheimer’s Disease Patient-Level Dataset
- Published January 5, 2021
- Birkenbihl, C., Westwood, S., Shi, L., Nevado-Holgado, A., Westman, E., Lovestone, S., & Hofmann-Apitius, M.
- Journal of Alzheimer's Disease
- https://doi.org/10.3233/JAD-200948
Highlights
- Alzheimer's patient-level dataset that is accessible for research purposes
- 1,702 study participants
- Multimodal data: transcriptomics, MRI, clinical data, genotyping, proteomics
- Longitudinal follow-up of participants
Abstract
Background Accessible datasets are of fundamental importance to the advancement of Alzheimer’s disease (AD) research. The AddNeuroMed consortium conducted a longitudinal observational cohort study with the aim to discover AD biomarkers. During this study, a broad selection of data modalities was measured including clinical assessments, magnetic resonance imaging, genotyping, transcriptomic profiling, and blood plasma proteomics. Some of the collected data were shared with third-party researchers. However, this data was incomplete, erroneous, and lacking in interoperability.
Objective To provide the research community with an accessible, multimodal, patient-level AD cohort dataset.
Methods We systematically addressed several limitations of the originally shared resources and provided additional unreleased data to enhance the dataset.
Results In this work, we publish and describe ANMerge, a new version of the AddNeuroMed dataset. ANMerge includes multimodal data from 1,702 study participants and is accessible to the research community via a centralized portal.
Conclusion ANMerge is an information rich patient-level data resource that can serve as a discovery and validation cohort for data-driven AD research, such as, for example, machine learning and artificial intelligence approaches.
Newsletter
If you liked this post, sign up to get updates in your email when I write something new! No spam ever.
Subscribe to the Newsletter